【打印本页】 【下载PDF全文】 【HTML】 查看/发表评论下载PDF阅读器关闭

←前一篇|后一篇→

过刊浏览    高级检索

本文已被:浏览 2016次   下载 1282 本文二维码信息
码上扫一扫!
胃癌患者癌组织及血浆中长链非编码RNA XIST的表达与临床意义
李江,史征,罗天航,聂明明,袁士杰,毕建威*
0
(第二军医大学长海医院胃肠外科, 上海 200433
共同第一作者
*通信作者)
摘要:
目的 探讨长链非编码RNA XIST(lncRNA-XIST)在胃癌患者癌组织和血浆中的表达水平及其临床意义。方法 收集2017年2月至7月于第二军医大学长海医院就诊的40例胃癌患者手术切除的胃癌组织及癌旁组织标本,抽取同期90例胃癌患者的术前血浆样本和90例健康体检者血浆样本。利用实时定量PCR(qPCR)检测上述标本中lncRNA-XIST的表达水平。采用非参数检验分析lncRNA-XIST表达水平与胃癌患者临床病理参数(年龄、性别、TNM分期、肿瘤最大径、淋巴结转移、分化程度、Ki-67阳性率)的关系。通过绘制受试者工作特征(ROC)曲线评价lncRNA-XIST在诊断胃癌时的效能。结果 胃癌组织中lncRNA-XIST表达较癌旁组织升高,胃癌患者血浆lncRNA-XIST表达高于健康体检者,差异均有统计学意义[0.150(0.094,0.247)vs 0.085(0.041,0.193)、0.189(0.119,0.256)vs 0.144(0.095,0.180),P均<0.05]。胃癌组织及血浆中的lncRNA-XIST表达水平与胃癌TNM分期、淋巴结转移、分化程度相关(癌组织:Z=3.147、2.729、2.393,血浆:Z=2.769、2.431、2.144;P均<0.05)。血浆lncRNA-XIST诊断胃癌ROC曲线下面积(AUC)为0.753(95%CI:0.681~0.825,P<0.001),截断(cut-off)值为0.197时灵敏度为51.1%、特异度为95.6%;诊断TNMⅠ~Ⅱ期胃癌AUC为0.694(95%CI:0.592~0.796,P<0.01),灵敏度为38.5%,特异度为95.6%;均高于癌胚抗原(CEA)和糖类抗原(CA)19-9、CA72-4单独及联合检测。结论 lncRNA-XIST在胃癌组织及胃癌患者血浆中表达升高,可能是胃癌的一个潜在的肿瘤标志物。
关键词:  长链非编码RNA  lncRNA-XIST  胃肿瘤  血浆  组织
DOI:10.16781/j.0258-879x.2017.11.1403
投稿时间:2017-09-19修订日期:2017-10-15
基金项目:国家自然科学基金(81472277).
Expression and clinical significance of long non-coding RNA XIST in tissue and plasma of gastric cancer
LI Jiang,SHI Zheng,LUO Tian-hang,NIE Ming-ming,YUAN Shi-jie,BI Jian-wei*
(Department of Gastrointestinal Surgery, Changhai Hospital, Second Military Medical University, Shanghai 200433, China
Co-first authors.
* Corresponding author)
Abstract:
Objective To investigate the expression levels of long non-coding RNA XIST (lncRNA-XIST) in cancer tissues and plasma of gastric cancer patients and its clinical significance. Methods Resected tumor tissues and adjacent non-tumor tissues of 40 patients with gastric cancer in Changhai Hospital of Second Military Medical University were collected from Feb. to Jul. 2017; the plasma samples were collected from 90 patients with gastric cancer and 90 healthy volunteers. The expression level of lncRNA-XIST in the above samples was detected by real-time quantitative PCR (qPCR).The relationship between the expression level of lncRNA-XIST and the clinicopathological parameters related to gastric cancer (age, gender, TNM stage, tumor maximum diameter, lymph node metastasis, differentiation, and Ki-67 positive rate) were analyzed by nonparametric test. The efficacy of plasma lncRNA-XIST in the diagnosis of gastric cancer was evaluated by plotting the receiver operating characteristic (ROC) curve. Results The expression of lncRNA-XIST in tumor tissues was significantly increased compared with adjacent non-tumor tissues (0.150[0.094, 0.247] vs 0.085[0.041, 0.193], P<0.05), and the lncRNA-XIST expression in plasma in the gastric cancer group was significantly higher than that in the healthy group (0.189[0.119, 0.256] vs 0.144[0.095, 0.180], P<0.05). The expression levels of lncRNA-XIST in plasma and cancer tissues of gastric cancer patients were related to TNM staging, lymph node metastasis and differentiation (cancer tissues:Z=3.147, 2.729 and 2.393; plasma:Z=2.769, 2.431 and 2.144; all P<0.05). Area under ROC curve (AUC) performed by plasmatic lncRNA-XIST for gastric cancer was 0.753 (95%CI 0.681-0.825, P<0.001); when the cut-off value was 0.197, the sensitivity was 51.1% and the specificity was 95.6%. The AUC of diagnosing gastric cancer in TNM Ⅰ-Ⅱ was 0.694(95%CI 0.592-0.796, P<0.01), with a sensitivity of 38.5% a the specificity of 95.6%. All values in above two cases were higher than those of carcino-embryonic antigen (CEA), carbohydrate antigen (CA)19-9, CA72-4 alone or combined detection. Conclusion The expression levels of lncRNA-XIST are increased in cancer tissues and plasma of gastric cancer patients, which may be a potential tumor marker for diagnosing gastric cancer.
Key words:  long non-coding RNAs  lncRNA-XIST  stomach neoplasms  plasma  tissues